Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Trabectedin

FDA-approved product (powder, intravenous), marketed as Evdi, Yondelis.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Trabectedin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Dedifferentiated liposarcoma
  • Leiomyosarcoma
  • Liposarcoma
  • Neoplasm
  • Ovarian cancer
  • Ovarian carcinoma
  • Ovarian neoplasm
  • Sarcoma
  • Soft tissue sarcoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other plant alkaloids and natural products
FDA pharmacologic class
Alkylating Drug FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA54.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli50.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae47.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis76.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Trabectedin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Trabectedin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study of Trabectedin in Patients With Advanced Ovarian Cancer

    NCT00050414 · start 2002-10

    Registered record
    Registry ID
    NCT00050414
    Conditions
    Ovarian Neoplasms; Endocrine Gland Neoplasms; Neoplasms by Site; Neoplasms; Ovarian Diseases; Adnexal Diseases; Genital Diseases, Female
    Interventions
    Trabectedin; Dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2002-10
    Completion
    2005-09
    Enrolment
    147

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOvarian Neoplasms; Endocrine Gland Neoplasms; Neoplasms by Site; Neoplasms +3 more
    InterventionTrabectedin; Dexamethasone
    PhasePhase 2
    Registry statusCompleted

  • Ecteinascidin 743 in Treating Patients With Malignant Mesothelioma

    NCT00027508 · start 2001-07

    Registered record
    Registry ID
    NCT00027508
    Conditions
    Malignant Mesothelioma
    Interventions
    trabectedin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2001-07
    Completion
    2002-02
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalignant Mesothelioma
    Interventiontrabectedin
    PhasePhase 2
    Registry statusTerminated

  • Ecteinascidin 743 in Treating Patients With Unresectable Advanced or Metastatic Soft Tissue Sarcoma

    NCT00017030 · start 2001-02

    Registered record
    Registry ID
    NCT00017030
    Conditions
    Sarcoma
    Interventions
    trabectedin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2001-02
    Completion
    2009-12
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSarcoma
    Interventiontrabectedin
    PhasePhase 2
    Registry statusCompleted

  • Ecteinascidin 743 in Treating Patients With Previously Treated Metastatic Osteosarcoma

    NCT00005625 · start 1999-12

    Registered record
    Registry ID
    NCT00005625
    Conditions
    Sarcoma
    Interventions
    trabectedin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1999-12
    Completion
    2003-09
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSarcoma
    Interventiontrabectedin
    PhasePhase 2
    Registry statusCompleted

  • Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma

    NCT00003939

    Registered record
    Registry ID
    NCT00003939
    Conditions
    Brain and Central Nervous System Tumors; Endometrial Cancer; Gastrointestinal Stromal Tumor; Ovarian Cancer; Sarcoma; Small Intestine Cancer
    Interventions
    trabectedin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    132

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBrain and Central Nervous System Tumors; Endometrial Cancer; Gastrointestinal Stromal Tumor; Ovarian Cancer +2 more
    Interventiontrabectedin
    PhasePhase 2
    Registry statusCompleted